1. Discuss the currently described and documented impact of pharmacists in various patient care settings.

2. Formulate a plan for applying novel pharmacy practice models to different areas of pharmacy practice.

3. Illustrate the current impact of provider status or advanced pharmacy practice models in optimizing patient care.

4. Differentiate the utilization or absence of provider status and advanced pharmacy practice models in the advancement of pharmacists and the ability to improve patient care.

1. Assess the mechanism ofaction for psychoactiveagents and how thisaffects human physiology.

2. Analyze published datasupporting the use ofpsychedelic agents invarious disease states.

3. Differentiate potentialdrug interactionsassociated with differentpsychedelic agents.

4. Illustrate the current FDAapproved dosage forms ofpsychedelic agentscurrent available on theUS market.

5. Evaluate the variances inpsychedelic products available to the consumer which are not FDA approved preparations.

6. Examine the current legal status of psychedelic agents in the United States and barriers to utilization.

7. Create a plan to provide care to patients who present on psychedelic agents for legitimate medical purposes.

1. Define key performance indicators (KPI) as they pertain to pharmacy management.

2. Review historical use of KPI in pharmacy practice.

3. Describe how to use metrics when presenting to the C-Suite.

4. List new ways that metrics can be used.

5. Describe the national approach to KPIs in pharmacy practice.

6. Discuss application of metrics to the real-world practice.

1. Summarize the latest developments and guidelines in the management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome.

2. Discuss the complex interplay between metabolic risk factors, chronic kidney disease (CKD), and the cardiovascular system.

3. Assess goals of therapy and efficacy for the management of CKM.

4. Outline emerging therapeutic interventions that demonstrate significant benefits in reducing morbidity and mortality within the CKM Syndrome patient cohort.

5. Identify interdisciplinary care models that consider the bidirectional associations between cardiac, metabolic and renal dysfunction, addressing the multifaceted aspects of CKM health.

6. Review the potential benefits and risks associated with new therapeutic approaches in the context of CKM disorders.

1. Identify how  global collaborations advance pharmacy practice and  addresses the unmet healthcare needs of global populations.

2. Discuss strategies for establishing and nurturing partnerships with international pharmaceutical organizations, academic institutions, and professional associations.

3. Define the role of pharmacists in influencing and shaping healthcare policies at both the national and international levels to improve preventative and medical services.

4. Discuss the potential impact of partnerships with NonGovernmental Organizations (NGOs) and government agencies on policy development and implementation.

5. Describe effective strategies for pharmacists and the significance of communitybased pharmacy initiatives in addressing local and global health challenges.

6. Highlight characteristics of successful collaboration models that enhance clinical and academic outcomes to improve overall community well-being to promote global health equity and access.

1. Analyze the impact of anticoagulation transitions in various healthcare settings, such as ambulatory oral anticoagulant use and subsequent inpatient transitions.

2. Formulate a plan to overcome barriers to transitions of care for patients on anticoagulation.

3. Examine common diabetes-related transition of care topics, including changes in inpatient to outpatient diabetes management, and steroid induced hyperglycemia.

4. Examine the inpatient use of outpatient diabetes technologies and implement strategies to minimize or prevent medication and/or technology errors that commonly occur in transitions of care for patients with diabetes.

5. Review legislative changes to opioid use disorder treatment, including DATA 2000 and elimination of requirements.

6. Design a treatment plan for opioid withdrawal and pain management in patients with opioid use disorder, with emphasis on how this affects transitions of care.

1. Describe the current indications for long-acting antiretroviral therapy in people living with HIV.

2. Explain the use of long-acting antiretroviral therapy in special populations.

3. Review investigational long-acting therapies for HIV treatment and cure.

4. Describe the current indications for long-acting antiretroviral therapy for HIV prevention.

5. Explain the use of long-acting HIV prevention in special populations.

6. Review investigational long-acting therapies for HIV prevention.

1. Outline evidence-based guidance for cardio-oncology practices with a focus on recently developed medications used in cancer treatment and supportive care.

2. Select diagnostic tools for screening and interpretation of cardiologic test results to guide medication use in cancer treatment and supportive care.

3. Discuss cardio-oncology considerations as it relates to survivorship. 

4. Describe the role of the pharmacist in incorporating cardio-oncology clinic into practice, including the challenges and limitations of implementing said practice.

5. Identify resources and processes for implementing cardio-oncology practices into oncology clinic.

1. Evaluate current guideline recommendations for patients presenting with acetaminophen toxicity. 

2. Develop an effective treatment regimen for the management of a patient presenting with acetaminophen toxicity.

3. Develop monitoring strategies for the different medications used to treat acetaminophen toxicity. 

4. Design an effective treatment plan for patients requiring adjunctive treatment options for acetaminophen toxicity. 

4. Design an effective treatment plan for patients requiring adjunctive treatment options for acetaminophen toxicity.

1. Summarize key deficiencies, barriers, and challenges in the implementation of treatments for acute ischemic stroke.

2. Critique the medical literature investigating the use of emerging treatment options in the management of acute ischemic stroke.

3. When given a patient case, develop a pharmacotherapy plan for treatment of acute ischemic stroke.

4. Develop a personal action plan for best practices associated with pharmacist participation in the care of the patient with acute ischemic stroke.

1. Identify appropriate candidates for deescalation in drug therapy.

2. Examine application of new evidence surrounding duration of pharmacotherapy in comparison to guidelines in various specialties.

3. Design a pharmacotherapy regimen for patients on dual antiplatelet therapy.

4. Design a pharmacotherapy regimen for patients with asthma using single maintenance and reliever therapy (SMART).

5. Design a pharmacotherapy regimen for patients on proton pump inhibitor therapy.

6. Design a pharmacotherapy regimen for patients on psychotropic medications.

1. Outline artificial and augmented intelligence (AI) applications currently available in practice.

2. Evaluate opportunities to improve precision evidence incorporation into guideline development and implementation into clinical practice.

3. Assess barriers and ethical considerations regarding implementation and clinical applications of AI.

4. Describe how AI can help develop national and international practice guidelines.

5. Examine opportunities to utilize AI to implement national and international practice guidelines into clinical practice.

6. Illustrate how future AI applications can impact patient care and guideline development.

2. Design a regimen for an older adult with diabetes considering goals and patient-related variables.

1. Compare the top 10 take-home messages from the 2023 Atrial Fibrillation (AF) Guidelines to recommendations from the 2014 and 2019 guidelines.

2. Evaluate 2023 AF guideline use in ambulatory care, focusing on the updated staging system's impact on patient management, emphasizing preventive measures and lifestyle modifications.

3. Develop an evidence-based treatment plan using patient-specific factors based on the 2023 AF guidelines, considering patient adherence, lifestyle modifications, and monitoring challenges.

1. Describe diagnosis and classification of Pulmonary Artery Hypertension through WHO groups.

2. Recognize underlying pathophysiologies of pulmonary hypertension.

3. Discuss pulmonary arterial hypertension risk stratification utilizing multi-parameter assessment tools.

4. Summarize updates in pharmacotherapy for pulmonary arterial hypertension.

5. Summarize evidence for advances in pharmacotherapy for pulmonary hypertension from interstitial lung disease.

1. Compare the spectrum of activity, pharmacokinetics, and pharmacodynamic properties of newly approved antibiotics for the treatment of difficult-to-treat gram-negative bacterial infections in adult and pediatric populations.

6. Identify clinical scenarios where novel antifungal agents offer efficacy or safety advantages over established treatments.

1. Describe the value of deprescribing within clinical practice.

2. List key medication classes that should be considered for deprescribing. 

3. Develop a plan to optimize medication management through deprescribing based on a patient's goals of care and prognosis.

4. Apply deprescribing communication techniques using the FRAME communication map.

1. Compare currently available pharmacological agents used in the treatment of obesity.  

2. Assess current guidelines in the management of obesity.

3. Evaluate the cardiovascular benefits of obesity pharmacotherapy and bariatric interventions.

4. Review the most commonly employed bariatric interventions and their impact on pharmacotherapy in patients with obesity.

5. Distinguish the roles of the interprofessional healthcare team in obesity management.

6. Examine possible new agents or therapeutic options in the management of obesity.

1. Review current national data and legislative changes addressing the opioid epidemic.

2. Examine harm reduction and universal screening practices and evidence for these practices in relation to the opioid epidemic.

3. Formulate an evidence-based comprehensive care plan for an individual presenting with OUD using current guidelines, clinical trial evidence, and medication characteristics.

4. Assess novel and emerging roles of pharmacists in managing pain and opioid use disorder across the continuum of care.

5. Implement recent guideline updates and clinical trial evidence surrounding the use of non-opioid analgesics in pain management in the care of an individual seeking treatment for acute/chronic pain.

1. Differentiate current mechanisms of reimbursement for pharmacist activities in various practice settings.

2. Construct novel approaches for obtaining reimbursement for pharmacist activities.

3. Assess logistical and legal challenges to expanding reimbursement or revenue generation.

4. Formulate funding and reimbursement proposals at an executive level.

1. ​​Analyze data showing the clinical benefits of continuous glucose monitors (CGMs).​

2. ​​Investigate barriers to CGM access in patients with diabetes.

3. Design an evidence-based treatment regimen for a patient with diabetes based on their ambulatory glucose profile.

4. ​​Given a patient case, identify risk factors for developing eDKA.

5. Distinguish between the characteristics of patients presenting with diabetic ketoacidosis (DKA) and euglycemic DKA (eDKA).

6. ​​Examine treatment standards for patients with eDKA.​

7. ​​Differentiate between the management of eDKA and DKA in patients with diabetes.​

1. Incorporate equitable and inclusive practices into gender based health across the lifespan.

2. Recommend FDA-approved medications and published literature for treatment of disease states across the lifespan.

3. Choose appropriate tools to assess and manage gender based care across the lifespan.

4. Utilize shared clinical decision-making and ways to empower pa ents to voice and learn about their sexual health and wellness.

5. Design comprehensive, inclusive, and equitable care plans for patients across the lifespan.

1. Assess clinical data evaluating the integration of PARP inhibitors into the treatment of breast, prostate, ovarian, and pancreatic cancers.

2. Identify patients who are appropriate for initiation of PARP inhibitor therapy. 

3. Describe the pathophysiology, incidence, and risk factors of PARP inhibitor-associated secondary myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). 

4. Summarize treatment paradigm changes with the updated classification of MDS and AML. 

5. Design a treatment strategy for patients with MDS or AML with previous PARP inhibitor exposure. 

1. Debate the utility of guideline-directed medical therapy in advanced heart failure.

2. Create an evidence-based therapy plan for a patient with pulmonary arterial hypertension.

3. Evaluate the evidence for rate versus rhythm control strategies in patients with atrial fibrillation.

4. Design an anticoagulation therapy and monitoring plan in the setting of drug-drug interactions.

1. Discuss the historical evolution and application of Entrustable Professional Activities (EPAs) in experiential education.

2. Describe the implications of the 2022 AACP Curriculum Outcomes and Entrustable Professional Activities (COEPA) on current educational practices.

3. Review EPA implementation for introductory and advanced pharmacy practice experiences (IPPEs and APPEs).

4. Explain the role of EPAs in competency-based assessment of pharmacist students.

5. Recognize the successes and challenges of academic pharmacists who have incorporated EPAs into IPPEs and APPEs.

6. Outline student-centered applications of EPAs for experiential education in the future.

1. Summarize clinical characteristics and supportive management of pericarditis and myocarditis.

2. ​Compare therapeutic plans for cardiac device infections.​

3. ​Differentiate between acute and long term management of vascular graft infections.​

4. ​Recommend optimal treatment strategies for complex and uncommon causes of bacterial endocarditis (including Q fever, Histoplasmosis, and Bartonella).​

5. ​Recognize updates in endocarditis management with special attention to diagnostics and patients who use IV drugs.​